Table 2.
Patient demographics and baseline characteristics (safety set).
| Parameters | Vildagliptin−Liraglutide (n = 32) | Liraglutide−Vildagliptin (n = 30) |
|---|---|---|
| Age (years) | 60.5 ± 11.23 | 60.1 ± 11.15 |
| ⩾65 (years), n (%) | 12 (37.5) | 10 (33.3) |
| Men, n (%) | 18 (56.3) | 11 (36.7) |
| Women, n (%) | 14 (43.8) | 19 (63.3) |
| Race, n (%) | ||
| White | 31 (96.9) | 30 (100.0) |
| Others | 1 (3.1) | 0 (0.0) |
| Body weight (kg) | 88.7 ± 14.77 | 92.0 ± 14.02 |
| BMI (kg/m2) | 30.5 ± 3.80 | 32.1 ± 3.19 |
| Duration of diabetes (years) | 7.0 ± 4.44 | 8.1 ± 7.21 |
| HbA1c (%) | 7.4 ± 0.58 | 7.3 ± 0.56 |
| FPG (mg/dl) | 159.8 ± 35.29 | 154.3 ± 30.17 |
Data are expressed as mean ± standard deviation, unless otherwise stated.
Safety set consisted of all patients who received at least one dose of the study medication during at least one study period and had at least one safety assessment after baseline.
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin.